Indian Pharma Focusing On R&D, Licensing – Ranbaxy Exec
This article was originally published in The Pink Sheet Daily
Executive Summary
Indian firms are flush with cash and looking to move from generic drugs to proprietary compounds, Ranbaxy’s Shyam Bishen tells “The Pink Sheet” DAILY.